14. Adenoid cystic carcinoma of lacrimal gland: A case report.

Adenoid cystic carcinoma is a rare tumour that represents less than 2% of all malignant tumours of the head and neck. It is primarily a tumour of adulthood with a peak incidence defined in the fourth to sixth decade of life. The onset of development is usually marked by exophthalmos or ptosis. Pain is frequent: a sign of carcinomatous involvement especially if it is associated with hypoaesthesia in the territory of the frontal nerve. The duration of symptoms is generally less than 6 months. The five histological patterns are: Basaloid (worst prognosis), sclerosing, cribriform, tubular and comedo carcinoma. We report a case of 35 year old male patient having left eye proptosis with upper lid ptosis and restricted eye movements diagnosed as having Adenoid Cystic Carcinoma of the lacrimal gland on the basis of histopathological examination. We describe its features and aggressive treatment approach which ensures appropriate management

Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity

Purpose: To evaluate the efficacy of a biosimilar ranibizumab (Razumab) on outcomes of retinopathy of prematurity (ROP) for the first time. Methods: This retrospective study included infants presenting with stage 3+ ROP either in zone 1 or zone 2 posterior or aggressive posterior ROP (APROP). All eligible infants received intravitreal razumab (0.25 mg/0.025 ml) monotherapy. Follow-up was continued monthly till complete retinal vascularization was achieved while retreatment with razumab was given when recurrent neovascularization was noted. In case of no recurrence but incomplete vascularization, laser photocoagulation was done to the residual avascular retina. Results: We included 118 eyes of 59 infants with a median gestational age of 30 weeks and median birth weight of 1250 grams. At presentation, APROP was found in 28 eyes (24%) of 14 babies while stage 3 disease was seen in zone 1 in another 28 eyes (24%) and the remaining 62 eyes (52%) had stage 3 ROP in zone 2 posterior region. Complete resolution of ROP along with complete vascularization was seen in 22 eyes (19%) at a median of 55 days (IQR = 31–56 days) and 42 eyes (35%) showed a recurrent neovascularization at a median of 51 days post razumab (IQR = 42–55 days). The cumulative incidence of recurrence of neovascularization (21%, 95% CI = 14%–29%) peaked at seven weeks and was significantly higher in eyes with APROP (43%, 95% CI = 27%–63%) compared to eyes without APROP (13.4%, 95%CI, 8%-22%) (P < 0.001). Conclusion: Razumab appears to be safe and effective in treating ROP, with about a third requiring reinjection at seven weeks after the first dose